Environmental Impact - Total greenhouse gas emissions for 2023 were 52,136 kg (CO2 equivalent), an increase from 48,413 kg in 2022, with emissions per employee rising to 1,212 kg from 1,181 kg[12]. - Scope 2 emissions from purchased electricity amounted to 45,363 kg in 2023, up from 42,792 kg in 2022[12]. - The density of greenhouse gas emissions per million HKD of total revenue increased to 1,145 kg in 2023 from 986 kg in 2022[12]. - The company produced 672 kg of indirect emissions from paper waste disposal in 2023, compared to 576 kg in 2022[12]. - The company generated approximately 39 kg of medical waste per employee in 2023, a decrease from 41 kg in 2022, with a density of 0.9 kg per million HKD of total revenue[16]. - The company is committed to sustainable long-term actions to manage its carbon footprint and reduce emissions[13]. - The company has not faced any environmental claims, lawsuits, or penalties during the reporting period[9]. - The company has implemented energy-saving measures, including monitoring indoor temperatures and upgrading to energy-efficient LED lighting[13]. - The company aims to maintain a comfortable indoor temperature of 25 degrees Celsius to balance comfort and energy consumption[13]. - The company has implemented waste reduction strategies and promotes recycling and waste segregation to minimize environmental impact[31]. - The company is committed to managing medical waste carefully, adhering to local regulations regarding waste disposal[26]. - The company has installed HEPA air purifiers in its Medicskin centers to improve indoor air quality[114]. - The group is committed to long-term sustainability by minimizing environmental impact through energy and water conservation efforts[137]. Financial Performance - The company's revenue for the fiscal year ending March 31, 2023, was HKD 45.5 million, a decrease of 7.3% from HKD 49.1 million in the previous fiscal year[49]. - The company recorded a loss attributable to shareholders of HKD 3.0 million, compared to a profit of HKD 3.9 million in the previous fiscal year, primarily due to a revenue decrease of approximately HKD 3.6 million and a foreign exchange loss of HKD 1.4 million[56]. - Other income and net gains decreased from HKD 1.2 million for the year ended March 31, 2022, to HKD 0.5 million for the year ended March 31, 2023, primarily due to a foreign exchange loss of HKD 1.4 million[59]. - Inventory costs increased to HKD 8.9 million for the year ended March 31, 2023, from HKD 7.0 million for the year ended March 31, 2022, representing 19.5% and 14.3% of the group's revenue for the respective years[60]. - Employee costs rose by HKD 2.0 million or 9.5% to HKD 22.5 million for the year ended March 31, 2023, attributed to increased salaries and performance bonuses for doctors[61]. - The group recorded a loss attributable to owners of HKD 3.0 million for the year ended March 31, 2023, compared to a profit of HKD 3.9 million for the year ended March 31, 2022[89]. - Total equity as of March 31, 2023, was HKD 11.2 million, down from HKD 14.2 million as of March 31, 2022[92]. - Cash and bank balances decreased to HKD 5.0 million as of March 31, 2023, from HKD 14.2 million as of March 31, 2022[92]. - The group did not declare a final dividend for the year ended March 31, 2023[91]. - The group had no interest-bearing borrowings as of March 31, 2023, resulting in a debt-to-equity ratio of zero[92]. - Operating cash generated for the year ended March 31, 2023, was HKD 4.3 million, unchanged from 2022[93]. - As of March 31, 2023, the group's lease liabilities were HKD 11.9 million, down from HKD 18.7 million in 2022[93]. - The group has unused bank financing of HKD 18.0 million under the SME Financing Guarantee Scheme as of March 31, 2023, compared to none in 2022[93]. - The capital commitment for injection to subsidiaries was HKD 0.5 million as of March 31, 2023, down from HKD 0.6 million in 2022[97]. - The group has no major investments or capital asset plans as of March 31, 2023[95]. Market and Business Strategy - The group aims to reduce emission intensity by 5% to 10% by 2023, using the fiscal year ending in 2018 as the baseline[26]. - The introduction of the EMFACE® treatment, a revolutionary facial treatment using RF and HIFESTM technology, aims to enhance service offerings and maintain competitiveness in the skincare industry[25]. - The reopening of the border between mainland China and Hong Kong is expected to attract more tourists, potentially positively impacting the group's revenue[26]. - The group plans to continue exploring and launching various new services and products to increase market share and create value for shareholders[25]. - The company plans to strategically expand and strengthen its market share in Hong Kong and mainland China while continuously improving service and product quality[51]. - The company aims to introduce new services and products as a key driver for business growth and to maintain its competitive position in the industry[57]. - The company has implemented measures to enhance online consultation services and e-commerce platforms for skincare products to adapt to the new normal[53]. - The company continues to evaluate market developments in new products, skills, and treatment technologies to provide the most suitable services to customers[57]. Employee and Training - The group has maintained a zero record for work-related injuries and fatalities during the reporting period[112]. - The company provided a total of 235 hours of training for employees during the reporting period, an increase from 171.5 hours in 2022[118]. - 100% of doctors and senior management participated in training, while 50% of general staff and 95% of medical assistants were trained[118]. - The average training hours completed per employee were 11.5 hours for male doctors and 7 hours for female doctors[118]. - The group had a total of 43 employees as of March 31, 2023, compared to 41 employees in the previous year[72]. - As of March 31, 2023, the group employed 28 full-time and 15 part-time employees, with total employee costs amounting to HKD 22.5 million, an increase from HKD 20.5 million in 2022[133]. Governance and Compliance - The group has complied with all relevant laws and regulations regarding environmental protection, health and safety, and employment during the reporting period[138]. - The company has established a whistleblowing policy to report misconduct, ensuring confidentiality and protection for whistleblowers[163]. - The company has received annual confirmation letters regarding the independence of all independent non-executive directors as per GEM Listing Rule 5.09[181]. - The group has maintained effective governance practices, ensuring the independence of its board members and adherence to regulatory requirements[181][184]. - The company has not been aware of any corruption lawsuits against it or its employees during the reporting period[161]. - The company has complied with the Prevention of Bribery Ordinance (Cap. 201) for the year ended March 31, 2023[164]. - Over 40% of employees have attended anti-corruption training provided by the Hong Kong Independent Commission Against Corruption[160]. - The company has established a clear recruitment process to comply with legal requirements and verify candidates' qualifications[119]. Community Engagement - The company donated HKD 3,000 to the Bright Eyes Engineering Charity Fund, demonstrating its commitment to positively impacting the community[186]. - The company emphasizes the importance of community engagement and resource utilization to support organizations driving positive social change[186].
密迪斯肌(08307) - 2023 - 年度财报